额颞叶失智症市场 - 2018-2028 年全球产业规模、份额、趋势、机会和预测，按药物类别、疾病适应症、配销通路、地区和竞争细分

2022年，全球额颞叶失智症（FTD）市场估值达到2.4136亿美元，预计在预测期内强劲成长，预计复合年增长率（CAGR）为6.39%，到2028年预计将达到3.466亿美元。额颞叶疾病是一种以大脑额叶或颞叶神经细胞退化为特征的神经系统疾病。这种疾病包括痴呆、进行性核上性麻痹和原发性进行性失语等多种疾病，显着影响行为、语言、运动和个性，损害个人进行日常活动的能力。额颞叶疾病，也称为额颞叶变性，是一类主要影响额叶和颞叶的脑部疾病。这些病症涉及神经细胞的逐渐丧失和痴呆的发展。通常，额颞叶疾病在 40 至 60 岁之间出现，但也可能在 60 岁之后发病。诊断后，额颞叶疾病患者的平均寿命约为 8-10 年。鑑于额颞叶疾病对医疗保健产业的重大影响，预计在预测期内将出现显着增长。

主要市场驱动因素：

• 1.增加 FTD 药物开发和资助：由于患者人数不断增加，非营利组织、疾病倡导团体和私人实体正在积极支持额颞叶变性 (FTD) 药物的开发。额颞叶退化协会(AFTD)、Bluefield 计画组织、Tau 联盟组织、阿兹海默症发现基金会(ADDF) 和CurePSP, Inc. 等着名非营利组织的研究资助计画在刺激重点研究工作方面发挥了关键作用。关于治疗额颞叶疾病。这些组织为临床和临床前试验提供支持，旨在测试能够减缓或阻止 FTD 和其他罕见神经系统疾病进展的新型疗法，从而促进市场成长。

市场概况
预测期	2024-2028
2022 年市场规模	24136万美元
2028 年市场规模	3.466亿美元
2023-2028 年复合年增长率	6.39%
成长最快的细分市场	医院药房
最大的市场	北美洲

• 2.赠款和政府资助：赠款和资金提供资源来支持以 FTD 为重点的研究计划，包括调查疾病的根本机制、确定潜在的药物靶点以及开发新的治疗方法。充足的资金可以增强 FTD 研究对科学家和研究人员的吸引力，促进合作，并促进创新治疗策略的探索。赠款和资金还有助于识别和验证有希望的 FTD 药物靶点，这对于开发解决该疾病根本原因的治疗方法至关重要。
• 3.失智症盛行率不断上升：由于失智症盛行率不断上升，额颞叶疾病治疗市场正在不断成长。痴呆症包括认知和沟通功能障碍，显示存在各种潜在疾病，包括大脑异常。由于目标疾病的盛行率不断上升以及受这些疾病影响的老年人口不断增加，预计该市场将会扩大。据世界卫生组织称，全球约有 5,000 万人患有痴呆症，每年诊断出约 1,000 万新病例。这凸显了该产业的持续发展。记忆丧失、混乱、行为改变和计划困难等认知缺陷是失智症患者面临的挑战，有助于市场成长。
• 4.政府对研发的投资不断增加：随着人们对痴呆症的普遍认识不断提高，医疗保健专业人员和公众对不同类型的痴呆症（包括 FTD）的了解也越来越多。这可以更好地识别、诊断和管理 FTD 病例。 FTD 的日益普及导致人们越来越有兴趣了解其根本原因和机制。这吸引了更多的研究资金，推动了 FTD 特定研究和药物开发的进步。随着 FTD 盛行率的升高，需要准确的早期诊断工具来区分 FTD 和其他形式的失智症。对改进诊断技术的需求正在推动 FTD 市场的创新。
• 5.准确诊断的技术进步：技术进步在推动额颞叶失智症（FTD）市场方面发挥着至关重要的作用。这些进步为 FTD 患者及其照护者提供了更准确的诊断、改进的患者管理、创新的治疗方法以及增强的支持系统。正子断层扫描 (PET) 和功能性磁振造影 (fMRI) 等尖端影像技术可更深入了解 FTD 患者的大脑结构和功能，透过识别脑萎缩和功能障碍的特定模式来帮助早期准确诊断FTD亚型相关。技术进步也有助于识别和验证与 FTD 相关的生物标记物，从而实现早期检测、追踪疾病进展和评估治疗效果。遗传分析技术的进步可以识别与 FTD 相关的基因突变，有助于更好地了解疾病的潜在遗传基础。技术工具能够根据个人的遗传和分子特征开发个人化治疗方法，有望根据特定的 FTD 亚型和患者特征来客製化治疗方法。远距医疗和远端监控技术使医疗保健专业人员能够评估 FTD 患者的认知和功能状态，而无需他们前往医疗机构，这对于行动不便或交通受限的患者尤其有利。

主要市场挑战：

• 1.神经系统疾病的误诊：额颞叶疾病常被误诊为其他神经或精神疾病，例如忧郁症、帕金森氏症、阿兹海默症或其他精神疾病。这种误诊可能会导致额颞叶疾病延迟开始适当的治疗以及无效甚至有害的治疗。准确的诊断对于正确的管理和及时的干预至关重要。误诊可能会导致不必要的医疗费用、浪费时间和资源，并错过有效治疗的机会。它还可以排除患者参与额颞叶疾病的临床试验，从而阻碍标靶治疗的开发。
• 2.药物试验失败率：高

神经系统疾病（包括额颞叶疾病）领域的临床试验失败带来了重大挑战，影响了这些疾病治疗的成长前景。临床试验失败意味着大量的时间、资源和资金投入，从而延迟了创新疗法的推出。失败的试验可能会对製药公司、研究机构和投资者带来经济损失，影响未来的研发计画。失败的试验可能会导致研究方向转变，偏离某些目标或方法，减缓整体进展，并阻碍研究人员追求神经系统疾病的创新治疗方法。临床试验失败导致缺乏成功的治疗方法，为患者和医疗保健提供者提供的治疗选择较少，从而限制了市场的成长。

主要市场趋势：

• 1.更高的药物批准和先进的治疗：治疗额颞叶疾病的新药的批准为患者提供了可能减缓疾病进展、控制症状和改善生活品质的治疗方法。这导致 FTD 患者和医疗保健提供者对治疗的需求更高。有效的治疗通常伴随着改进的诊断方法、生物标记和筛检工具，有助于早期诊断和患者识别。药物批准引起了媒体的关注，并提高了患者、照护者和公众的认识，导致更多的人寻求 FTD 的诊断和治疗方案。
• 2. FDA 的孤儿药开发奖励措施：美国食品药物管理局（FDA）提供的孤儿药开发激励措施有可能显着增加额颞叶失智症（FTD）市场的治疗需求。孤儿药旨在治疗罕见疾病和病症，包括许多神经退化性疾病，如 FTD。 FDA 为研究孤儿药的药物开发商提供一定的经济激励，包括降低监管提交和行销申请的费用。获得 FDA 批准的孤儿药将获得更大的市场独占权，为 FTD 治疗创造更有利的商业环境。

细分洞见：

药物类别见解：治疗额颞叶疾病的全球市场分为各种药物类别，包括抗精神病药物、认知增强剂、中枢神经系统兴奋剂、抗忧郁药物等。其中，抗忧郁药物预计将在预测期内带来利润丰厚的机会。抗忧郁药物主要用于治疗忧郁症和其他病症，包括心境恶劣、强迫症 (OCD)、焦虑症、神经性疼痛、饮食失调和慢性疼痛等。选择性血清素再摄取抑制剂（SSRI）已被证明对治疗额颞叶疾病有益。

疾病适应症洞察：额颞叶失智症在 2022 年占额颞叶失智症市场最大的市场份额，预计在预测期内将增长。预计原发性进行性失语症在预测期内将表现出最高的年复合成长率。

目录

第 1 章：产品概述

• 市场定义
• 市场范围
  • 涵盖的市场
  • 考虑学习的年份
  • 主要市场区隔

第 2 章：研究方法

• 研究目的
• 基线方法
• 主要产业伙伴
• 主要协会和二手资料来源
• 预测方法
• 数据三角测量与验证
• 假设和限制

第 3 章：执行摘要

• 市场概况
• 主要市场细分概述
• 主要市场参与者概述
• 重点地区/国家概况
• 市场驱动因素、挑战、趋势概述

第 4 章：客户之声

第 5 章：临床试验分析

• 正在进行的临床试验
• 已完成的临床试验
• 终止的临床试验
• 按开发阶段分類的管道细目
• 管道细分（按状态）
• 按研究应用分類的管道细分
• 按地区分類的管道明细
• 临床试验热图

第 6 章：全球额颞叶失智症市场展望

• 市场规模及预测
  • 按价值
• 市占率及预测
  • 依药物类别（认知增强剂、抗精神病药、抗忧郁剂、中枢神经系统兴奋剂和其他药物类别）
  • 依疾病指征（额颞叶失智症、原发性进行性失语症及运动障碍）
  • 按配销通路（医院药房、零售药房和网路药房）
  • 按地区
  • 按公司划分 (2022)
• 市场地图

第 7 章：北美额颞叶失智症市场展望

• 市场规模及预测
  • 按价值
• 市占率及预测
  • 按药物类别
  • 按疾病适应症
  • 按配销通路
  • 按国家/地区
• 北美：国家分析
  • 美国
  • 加拿大
  • 墨西哥

第 8 章：欧洲额颞叶失智症市场展望

• 市场规模及预测
  • 按价值
• 市占率及预测
  • 按药物类别
  • 按疾病适应症
  • 按配销通路
  • 按国家/地区
• 欧洲：国家分析
  • 德国
  • 英国
  • 义大利
  • 法国
  • 西班牙

第 9 章：亚太地区额颞叶失智症市场展望

• 市场规模及预测
  • 按价值
• 市占率及预测
  • 按药物类别
  • 按疾病适应症
  • 按配销通路
  • 按国家/地区
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

第 10 章：南美洲额颞叶失智症市场展望

• 市场规模及预测
  • 按价值
• 市占率及预测
  • 按药物类别
  • 按疾病适应症
  • 按配销通路
  • 按国家/地区
• 南美洲：国家分析
  • 巴西
  • 阿根廷
  • 哥伦比亚

第 11 章：中东和非洲额颞叶失智症市场展望

• 市场规模及预测
  • 按价值
• 市占率及预测
  • 按药物类别
  • 按疾病适应症
  • 按配销通路
  • 按国家/地区
• MEA：国家分析
  • 南非额颞叶失智症
  • 沙乌地阿拉伯 额颞叶失智症
  • 阿联酋额颞叶失智症

第 12 章：市场动态

• 司机
• 挑战

第 13 章：市场趋势与发展

• 近期发展
• 併购
• 产品发布

第 14 章：全球额颞叶失智症市场：SWOT 分析

第 15 章：波特的五力分析

• 产业竞争
• 新进入者的潜力
• 供应商的力量
• 客户的力量
• 替代产品的威胁

第16章：竞争格局

• 商业概览
• 服务内容
• 最近的发展
• 主要人员
• SWOT分析
  • Transposon Therapeutics
  • Alector Inc.
  • Denali Therapeutics Inc.
  • Pfizer Inc.
  • Johnson & Johnson Services Inc.
  • Prevail Therapeutics
  • Wave Life Sciences
  • AstraZeneca plc
  • GlaxoSmithKline plc
  • TauRx Pharmaceuticals Ltd.

第 17 章：策略建议

第 18 章：关于我们与免责声明

The Global Frontotemporal Dementia (FTD) Market reached a valuation of USD 241.36 Million in 2022 and is poised for robust growth in the forecast period, projecting a Compound Annual Growth Rate (CAGR) of 6.39% and expected to reach USD 346.60 Million through 2028. Frontotemporal diseases represent a neurological condition characterized by the degeneration of nerve cells in the frontal or temporal lobes of the brain. This condition, which encompasses various disorders such as dementia, progressive supranuclear palsy, and primary progressive aphasia, significantly affects behavior, language, movement, and personality, impairing individuals' ability to perform daily activities. Frontotemporal disorders, also known as frontotemporal lobar degeneration, are a category of brain disorders primarily impacting the frontal and temporal lobes. These conditions involve the progressive loss of nerve cells and the development of dementia. Typically, frontotemporal disorders manifest between the ages of 40 and 60, although onset can occur after the age of 60. Following diagnosis, individuals with frontotemporal disorders have an average life expectancy of approximately 8-10 years. Given its substantial impact on the healthcare sector, frontotemporal disorders are expected to experience significant growth in the forecast period.

Key Market Drivers:

• 1. Increasing FTD Drug Development and Funding: Non-profit organizations, disease advocacy groups, and private entities are actively supporting the development of drugs for Frontotemporal Degeneration (FTD) due to the expanding patient population. Research funding initiatives from prominent non-profit organizations like the Association for Frontotemporal Degeneration (AFTD), Bluefield Project Organization, Tau Consortium Organization, Alzheimer Discovery Foundation (ADDF), and CurePSP, Inc., have played a pivotal role in stimulating research efforts focused on treating frontotemporal disorders. These organizations provide support for both clinical and preclinical trials aimed at testing novel therapeutics that can slow down or halt the progression of FTD and other rare neurological diseases, contributing to market growth.

Market Overview
Forecast Period	2024-2028
Market Size 2022	USD 241.36 Million
Market Size 2028	USD 346.60 Million
CAGR 2023-2028	6.39%
Fastest Growing Segment	Hospital Pharmacy
Largest Market	North America

• 2. Grants and Government Funding: Grants and funding provide resources to support FTD-focused research initiatives, including investigations into the underlying mechanisms of the disease, identification of potential drug targets, and the development of novel therapeutic approaches. Adequate funding enhances the attractiveness of FTD research for scientists and researchers, fosters collaboration, and facilitates the exploration of innovative therapeutic strategies. Grants and funding also assist in the identification and validation of promising drug targets for FTD, which is crucial for developing treatments that address the root causes of the disease.

• 3. Increasing Prevalence of Dementia: The Frontotemporal Disorders Treatment Market is witnessing growth due to the rising prevalence of dementia. Dementia encompasses cognitive and communicative dysfunction, indicative of various underlying conditions, including brain abnormalities. The market is projected to expand due to the growing prevalence of target diseases and a rising geriatric population affected by these conditions. According to the World Health Organization, approximately 50 million individuals worldwide suffer from dementia, with around 10 million new cases diagnosed annually. This underscores the continued development of this sector. Cognitive deficits such as memory loss, confusion, behavioral changes, and planning difficulties are among the challenges faced by individuals with dementia, contributing to market growth.

• 4. The Rising Investment in Research and Development by Governments: As general awareness about dementia increases, healthcare professionals, and the public are becoming more knowledgeable about different types of dementia, including FTD. This results in better recognition, diagnosis, and management of FTD cases. The growing prevalence of FTD has led to increased interest in understanding its underlying causes and mechanisms. This has attracted more research funding, driving advancements in FTD-specific research and drug development. With a higher prevalence of FTD, there is a need for accurate and early diagnostic tools to distinguish FTD from other forms of dementia. The demand for improved diagnostic technologies is driving innovation in the FTD market.

• 5. Technological Advancements for Accurate Diagnosis: Technological advancements are playing a crucial role in boosting the Frontotemporal Dementia (FTD) market. These advancements enable more accurate diagnosis, improved patient management, innovative treatments, and enhanced support systems for individuals with FTD and their caregivers. Cutting-edge imaging technologies such as positron emission tomography (PET) and functional magnetic resonance imaging (fMRI) provide deeper insights into the brain structure and function of individuals with FTD, aiding in early and accurate diagnosis by identifying specific patterns of brain atrophy and dysfunction associated with FTD subtypes. Technological advancements also facilitate the identification and validation of biomarkers associated with FTD, enabling earlier detection, tracking of disease progression, and assessment of treatment efficacy. Advances in genetic analysis techniques allow for the identification of genetic mutations associated with FTD, contributing to a better understanding of the disease's underlying genetic basis. Technological tools enable the development of personalized treatment approaches based on an individual's genetic and molecular profile, holding promise for tailoring therapies to specific FTD subtypes and patient characteristics. Telemedicine and remote monitoring technologies allow healthcare professionals to assess FTD patients' cognitive and functional status without requiring them to visit healthcare facilities, particularly beneficial for patients with mobility or transportation limitations.

Key Market Challenges:

• 1. Misdiagnosis of Neurological Disorders: Frontotemporal disorders are often misdiagnosed as other neurological or psychiatric conditions such as depression, Parkinson's disease, Alzheimer's disease, or other psychiatric disorders. This misdiagnosis can lead to delayed initiation of appropriate treatment for frontotemporal disorders and ineffective or even harmful treatments. Accurate diagnosis is crucial for proper management and timely intervention. Misdiagnosis can result in unnecessary medical expenses, wasted time and resources, and missed opportunities for effective treatments. It can also exclude patients from participating in clinical trials for frontotemporal disorders, hindering the development of targeted therapies.

• 2. Drug Trial Failures: The high rate

of clinical trial failures in the field of neurological conditions, including frontotemporal disorders, poses a significant challenge that impacts the growth prospects of treatments for these conditions. Clinical trial failures represent a substantial investment of time, resources, and funding, delaying the availability of innovative treatments. Failed trials can lead to financial losses for pharmaceutical companies, research institutions, and investors, impacting future research and development initiatives. Failed trials can result in a shift in research direction, away from certain targets or approaches, slowing overall progress, and discouraging researchers from pursuing innovative treatment approaches for neurological conditions. The lack of successful treatments resulting from clinical trial failures can limit market growth by offering fewer treatment options for patients and healthcare providers.

Key Market Trends:

• 1. Higher Drug Approvals and Advanced Treatment: The approval of new drugs for frontotemporal disorders provides patients with access to treatments that can potentially slow down disease progression, manage symptoms, and improve quality of life. This leads to higher demand for treatments among FTD patients and healthcare providers. Effective treatments often come with improved diagnostic methods, biomarkers, and screening tools, facilitating early diagnosis and patient identification. Drug approvals garner media attention and raise awareness among patients, caregivers, and the general public, leading to more individuals seeking diagnosis and treatment options for FTD.

• 2. Orphan Drug Development Incentives by FDA: The orphan drug development incentives provided by the U.S. Food and Drug Administration (FDA) have the potential to significantly boost the demand for treatments in the Frontotemporal Dementia (FTD) market. Orphan drugs are intended to treat rare diseases and conditions, including many neurodegenerative disorders like FTD. The FDA provides certain financial incentives to drug developers working on orphan drugs, including reduced fees for regulatory submissions and marketing applications. Orphan drugs that receive FDA approval are granted extended market exclusivity, creating a more favorable commercial environment for FTD treatments.

Segmental Insights:

Drug Class Insights: The global market for the treatment of frontotemporal disorders is segmented into various drug classes, including antipsychotics, cognitive enhancers, CNS stimulants, antidepressants, and others. Among these, antidepressants are expected to present lucrative opportunities during the forecast period. Antidepressant drugs are primarily used for the management of depressive disorders and other conditions, including dysthymia, obsessive-compulsive disorder (OCD), anxiety disorders, neuropathic pain, eating disorders, and chronic pain, among others. Selective serotonin reuptake inhibitors (SSRIs) have proven beneficial in treating frontotemporal disorders.

Disease Indication Insights: Frontotemporal Dementia accounted for the largest market share in the Frontotemporal Dementia Market in 2022 and is projected to grow during the forecast period. Primary Progressive Aphasia is expected to exhibit the highest compound annual growth rate during the forecast period.

Regional Insights: North America emerged as the dominant player in the Frontotemporal Disorders Treatment Market in 2022, driven by growing awareness, advanced healthcare facilities, and rising income levels. The Asia Pacific region is projected to witness a higher compound annual growth rate (CAGR) during the forecast period, fueled by increasing prevalence of frontotemporal disorders and favorable reimbursement policies.

Key Market Players

• Transposon Therapeutics
• Alector Inc.
• Denali Therapeutics Inc.
• Pfizer Inc.
• Johnson & Johnson Services Inc.
• Prevail Therapeutics
• Wave Life Sciences
• AstraZeneca plc
• GlaxoSmithKline plc
• TauRx Pharmaceuticals Ltd.

Report Scope:

In this report, the Global Frontotemporal Dementia Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Frontotemporal Dementia Market, By Drug Class:

• Cognitive Enhancers
• Antipsychotics
• Antidepressants
• CNS Stimulants
• Other Drug Classes

Frontotemporal Dementia Market, By Disease Indication:

• Frontotemporal Dementia
• Primary Progressive Aphasia
• Movement Disorders

Frontotemporal Dementia Market, By Distribution Channel:

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Frontotemporal Dementia Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia-Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE
• Kuwait
• Turkey
• Egypt

Competitive Landscape

• Company Profiles: Detailed analysis of the major companies present in the Global Frontotemporal Dementia Market.

Available Customizations:

• Global Frontotemporal Dementia market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validations
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Clinical Trial Analysis

• 5.1. Ongoing Clinical Trials
• 5.2. Completed Clinical Trials
• 5.3. Terminated Clinical Trials
• 5.4. Breakdown of Pipeline, By Development Phase
• 5.5. Breakdown of Pipeline, By Status
• 5.6. Breakdown of Pipeline, By Study Application
• 5.7. Breakdown of Pipeline, By Region
• 5.8. Clinical Trials Heat Map

6. Global Frontotemporal Dementia Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Drug Class (Cognitive Enhancers, Antipsychotics, Antidepressants, CNS Stimulants, and Other Drug Classes)
  • 6.2.2. By Disease Indication (Frontotemporal Dementia, Primary Progressive Aphasia, and Movement Disorders)
  • 6.2.3. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies)
  • 6.2.4. By Region
  • 6.2.5. By Company (2022)
• 6.3. Market Map

7. North America Frontotemporal Dementia Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Drug Class
  • 7.2.2. By Disease Indication
  • 7.2.3. By Distribution Channel
  • 7.2.4. By Country
• 7.3. North America: Country Analysis
  • 7.3.1. United States Frontotemporal Dementia Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Drug Class
      • 7.3.1.2.2. By Disease Indication
      • 7.3.1.2.3. By Distribution Channel
  • 7.3.2. Canada Frontotemporal Dementia Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Drug Class
      • 7.3.2.2.2. By Disease Indication
      • 7.3.2.2.3. By Distribution Channel
  • 7.3.3. Mexico Frontotemporal Dementia Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Drug Class
      • 7.3.3.2.2. By Disease Indication
      • 7.3.3.2.3. By Distribution Channel

8. Europe Frontotemporal Dementia Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Drug Class
  • 8.2.2. By Disease Indication
  • 8.2.3. By Distribution Channel
  • 8.2.4. By Country
• 8.3. Europe: Country Analysis
  • 8.3.1. Germany Frontotemporal Dementia Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Drug Class
      • 8.3.1.2.2. By Disease Indication
      • 8.3.1.2.3. By Distribution Channel
  • 8.3.2. United Kingdom Frontotemporal Dementia Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Drug Class
      • 8.3.2.2.2. By Disease Indication
      • 8.3.2.2.3. By Distribution Channel
  • 8.3.3. Italy Frontotemporal Dementia Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecasty
      • 8.3.3.2.1. By Drug Class
      • 8.3.3.2.2. By Disease Indication
      • 8.3.3.2.3. By Distribution Channel
  • 8.3.4. France Frontotemporal Dementia Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Drug Class
      • 8.3.4.2.2. By Disease Indication
      • 8.3.4.2.3. By Distribution Channel
  • 8.3.5. Spain Frontotemporal Dementia Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Drug Class
      • 8.3.5.2.2. By Disease Indication
      • 8.3.5.2.3. By Distribution Channel

9. Asia-Pacific Frontotemporal Dementia Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Drug Class
  • 9.2.2. By Disease Indication
  • 9.2.3. By Distribution Channel
  • 9.2.4. By Country
• 9.3. Asia-Pacific: Country Analysis
  • 9.3.1. China Frontotemporal Dementia Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Drug Class
      • 9.3.1.2.2. By Disease Indication
      • 9.3.1.2.3. By Distribution Channel
  • 9.3.2. India Frontotemporal Dementia Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Drug Class
      • 9.3.2.2.2. By Disease Indication
      • 9.3.2.2.3. By Distribution Channel
  • 9.3.3. Japan Frontotemporal Dementia Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Drug Class
      • 9.3.3.2.2. By Disease Indication
      • 9.3.3.2.3. By Distribution Channel
  • 9.3.4. South Korea Frontotemporal Dementia Market Outlook
    • 9.3.4.1. Market Size & Forecast
      • 9.3.4.1.1. By Value
    • 9.3.4.2. Market Share & Forecast
      • 9.3.4.2.1. By Drug Class
      • 9.3.4.2.2. By Disease Indication
      • 9.3.4.2.3. By Distribution Channel
  • 9.3.5. Australia Frontotemporal Dementia Market Outlook
    • 9.3.5.1. Market Size & Forecast
      • 9.3.5.1.1. By Value
    • 9.3.5.2. Market Share & Forecast
      • 9.3.5.2.1. By Drug Class
      • 9.3.5.2.2. By Disease Indication
      • 9.3.5.2.3. By Distribution Channel

10. South America Frontotemporal Dementia Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Drug Class
  • 10.2.2. By Disease Indication
  • 10.2.3. By Distribution Channel
  • 10.2.4. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Frontotemporal Dementia Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Drug Class
      • 10.3.1.2.2. By Disease Indication
      • 10.3.1.2.3. By Distribution Channel
  • 10.3.2. Argentina Frontotemporal Dementia Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Drug Class
      • 10.3.2.2.2. By Disease Indication
      • 10.3.2.2.3. By Distribution Channel
  • 10.3.3. Colombia Frontotemporal Dementia Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Drug Class
      • 10.3.3.2.2. By Disease Indication
      • 10.3.3.2.3. By Distribution Channel

11. Middle East and Africa Frontotemporal Dementia Market Outlook

• 11.1. Market Size & Forecast
  • 11.1.1. By Value
• 11.2. Market Share & Forecast
  • 11.2.1. By Drug Class
  • 11.2.2. By Disease Indication
  • 11.2.3. By Distribution Channel
  • 11.2.4. By Country
• 11.3. MEA: Country Analysis
  • 11.3.1. South Africa Frontotemporal Dementia Market Outlook
    • 11.3.1.1. Market Size & Forecast
      • 11.3.1.1.1. By Value
    • 11.3.1.2. Market Share & Forecast
      • 11.3.1.2.1. By Drug Class
      • 11.3.1.2.2. By Disease Indication
      • 11.3.1.2.3. By Distribution Channel
  • 11.3.2. Saudi Arabia Frontotemporal Dementia Market Outlook
    • 11.3.2.1. Market Size & Forecast
      • 11.3.2.1.1. By Value
    • 11.3.2.2. Market Share & Forecast
      • 11.3.2.2.1. By Drug Class
      • 11.3.2.2.2. By Disease Indication
      • 11.3.2.2.3. By Distribution Channel
  • 11.3.3. UAE Frontotemporal Dementia Market Outlook
    • 11.3.3.1. Market Size & Forecast
      • 11.3.3.1.1. By Value
    • 11.3.3.2. Market Share & Forecast
      • 11.3.3.2.1. By Drug Class
      • 11.3.3.2.2. By Disease Indication
      • 11.3.3.2.3. By Distribution Channel

12. Market Dynamics

• 12.1. Drivers
• 12.2. Challenges

13. Market Trends & Developments

• 13.1. Recent Development
• 13.2. Mergers & Acquisitions
• 13.3. Product Launches

14. Global Frontotemporal Dementia Market: SWOT Analysis

15. Porter's Five Forces Analysis

• 15.1. Competition in the Industry
• 15.2. Potential of New Entrants
• 15.3. Power of Suppliers
• 15.4. Power of Customers
• 15.5. Threat of Substitute Product

16. Competitive Landscape

• 16.1. Business Overview
• 16.2. Service Offerings
• 16.3. Recent Developments
• 16.4. Key Personnel
• 16.5. SWOT Analysis
  • 16.5.1. Transposon Therapeutics
  • 16.5.2. Alector Inc.
  • 16.5.3. Denali Therapeutics Inc.
  • 16.5.4. Pfizer Inc.
  • 16.5.5. Johnson & Johnson Services Inc.
  • 16.5.6. Prevail Therapeutics
  • 16.5.7. Wave Life Sciences
  • 16.5.8. AstraZeneca plc
  • 16.5.9. GlaxoSmithKline plc
  • 16.5.10. TauRx Pharmaceuticals Ltd.

17. Strategic Recommendations

18. About Us & Disclaimer